Ipca Laboratories Ltd (IPCALAB) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported a strong performance in Q4 FY26, with the domestic formulation business growing by approximately 12%.
- Standalone EBITDA margin for Q4 FY26 saw a significant improvement of 408 basis points, reaching 25.27% compared to 21.19% in the same quarter of the previous year, driven by a favorable product mix.
- The US business, on a consolidated basis including Unichem, demonstrated a growth of around 10% in the quarter, contributing to the overall positive performance.
- The company has provided a robust growth guidance of 12-13% for the upcoming financial year (FY27) on a consolidated basis.
- Management highlighted that while raw material costs have started to increase, they are confident in their ability to pass on most of the costs and maintain healthy margins, guiding for a consolidated EBITDA margin of around 22-22.3% for FY27.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.